

This listing of claims will replace all prior versions, and listings, of claims in the application.

*Listing of Claims:*

1. *(cancelled)*

2. *(currently amended)* A compound ~~according to Claim 1~~ selected from the group consisting of:

- a) 3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one,
- b) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-methoxy-3H-quinazolin-4-one;
- c) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-methyl-3H-quinazolin-4-one;
- d) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-3H-quinazolin-4-one;
- e) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methoxy-3H-quinazolin-4-one;
- f) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-3H-quinazolin-4-one;
- g) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methyl-3H-quinazolin-4-one;
- h) 3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-naphthalen-2-yl-3H-quinazolin-4-one; and
- i) 3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-naphthalen-2-yl-3H-quinazolin-4-one;

and physiologically acceptable salts and solvates thereof.

3. *(currently amended)* A process for preparing a compound of claim ~~1~~ 2, comprising the step of: treating a solvate or hydrate of a compound of claim 1 with a solvolysing or hydrogenolysing agent

4. *(currently amended)* A pharmaceutical composition, comprising:

a compound according to ~~Claim 1~~ claim 2 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable excipient.

5. *(currently amended)* A method of antagonizing glycoprotein IbIX receptors, comprising the step of:

administering an effective amount of a compound according to ~~Claim 1~~ claim 2 or a pharmaceutically acceptable salt or solvate thereof to a patient in need thereof.

6. *(currently amended)* A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising the step of:

administering an effective amount of a compound according to ~~Claim 1~~ claim 2 or a pharmaceutically acceptable salt or solvate thereof to a patient in need thereof.

7. *(cancelled)*

8. *(currently amended)* A method of preventing adhesion on a foreign surface in contact with a patient, comprising the step of:

administering an effective amount of a compound according to ~~Claim 1~~ claim 2 or a pharmaceutically acceptable salt or solvate thereof to said patient.

9. *(previously presented)* A method according to claim 6, wherein said sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndromes, peripheral circulatory disorders, stroke, transient ischaemic attacks, or reocclusion/restenosis after angioplasty/stent implantations.

10. *(previously presented)* A method according to claim 8, wherein said foreign surface is the surface of an implant, catheter, or heart pacemaker.

11. *(cancelled)*